摘要
目的:通过在卵巢癌细胞SKOV3中使用血管内皮生长因子(VEGF)抗体贝伐单抗,了解脐血内皮祖细胞(EPCs)对卵巢癌细胞SKOV3增殖、迁移、黏附和凋亡能力的影响。方法:在成功建立EPCs和卵巢癌细胞SKOV3体外培育模型后,将实验分为SKOV3单独培养组(SKOV3组),SKOV3+EPCs共培养组(SKOV3+EPCs组),SKOV3+100μg/ml的贝伐单抗共培养组(SKOV3+贝伐单抗组)和SKOV3+EPCs+100μg/ml的贝伐单抗共培养组(SKOV3+EPCs+贝伐单抗组),并比较4组SKOV3的增殖、凋亡、迁移和黏附能力的变化。结果:①SKOV3+EPCs组SKOV3的增殖能力、穿膜细胞数和OD值高于SKOV3组(P<0.05,P<0.01);②SKOV3+贝伐单抗组SKOV3的增殖能力、穿膜细胞数、凋亡率低于SKOV3组(P<0.05,P<0.01):③SK—OV3+EPCs+贝伐单抗组SKOV3的增殖活性、穿膜细胞数、凋亡率低于SKOV3+EPCs组(P<0.05,P<0.01),而OD值显著高于SKOV3+EPCs组(P<0.01)。结论:共培养条件下EPCs能促进SKOV3生物学功能,贝伐单抗则相反,EPCs能协同贝伐单抗抑制SKOV3的生物学功能。
Objective：To observe the influence of endothelial progenitor cells（EPCs） and bevacizumab on ovarian cancer SKOV3 cells. Methods：After establishing in vitro co-cultured model of EPCs and SKOV3 cells, the experiment was divided into four groups as follows： SKOV3 group, SKOV3 ＋ EPCs co-culture group （SKOV3 ＋ EPCs group）, SKOV3 ＋ 100μg/ml bevacizumab group （SKOV3 ＋ bevacizumab group） and SKOV3 ＋ EPCs co-culture with 100 μg/ml bevacizumab group （SKOV3 ＋ EPCs ＋ bevacizumab group）. The proliferation, apoptosis, migration and adhesion capability were compared among groups. Results：（1） The proliferation, migration and adhesion activities in SKOV3 ＋ EPCs group were higher than those in SK- OV3 group （P 〈0.05, P 〈 0.01 ） ; （2）The proliferation, migration and apoptosis activities in SKOV3 ＋ bevaci- zumab group were lower than those in SKOV3 group （ P 〈 0.05, P 〈 0. 01 ） ; （3） The proliferation, apoptosis and migration activities in SKOV3 ＋ EPCs ＋ bevacizumab group was lower than those in SKOV3 ＋ EPCs group （P〈0. 05,P〈0. 01 ）, but the adhesion activity was significantly higher in SKOV3 ＋ EPCs ＋ bevaci- zumab group （P 〈 0.01 ）. Conclusions： The biological activity of SKOV3 was promoted co-cultured with EPCs, while inhibited by bevacizumab. EPCs had a synergistical effect to bevacizumab.
出处
《实用妇产科杂志》
CAS
CSCD
北大核心
2014年第3期191-195,共5页
Journal of Practical Obstetrics and Gynecology
基金
国家自然科学基金(编号:30801235)
关键词
内皮祖细胞
卵巢癌细胞SKOV3
贝伐单抗
体外
Eendothelial progenitor cells
Ovarian cancer cell line SKOV3
Bevacizumab
In vitro
